ARROWHEAD PHARMACEUTICALS, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| CommonStock | Amount ($) | AdditionalPaid-InCapital | Accumulated Other Comprehensive Income | AccumulatedDeficit | Non-controlling Interest | Total | |
|---|---|---|---|---|---|---|---|
| Balance at September 30, 2024 | 124,376 | $217 | $1,806,000 | $4,750 | $(1,625,523) | $5,619 | $191,063 |
| Stock-based compensation | — | — | 15,209 | — | — | — | 15,209 |
| Exercise of stock options | 70 | — | 634 | — | — | — | 634 |
| Common stock - restricted stock units vesting | 209 | — | — | — | — | — | — |
| Issuance of pre-funded warrants | — | — | 25,000 | — | — | — | 25,000 |
| Foreign currency translation adjustments | — | — | — | (106) | — | — | (106) |
| Unrealized losses on available-for-sale securities | — | — | — | (507) | — | — | (507) |
| Net loss | — | — | — | — | (173,085) | (2,133) | (175,218) |
| Balance at December 31, 2024 | 124,655 | $217 | $1,846,843 | $4,137 | $(1,798,608) | $3,486 | $56,075 |
| Stock-based compensation | — | — | 16,027 | — | — | — | 16,027 |
| Exercise of stock options | 353 | — | 2,619 | — | — | — | 2,619 |
| Common stock - restricted stock units vesting | 1,128 | 1 | — | — | — | — | 1 |
| Common stock issued | 11,926 | 12 | 241,375 | — | — | — | 241,387 |
| Foreign currency translation adjustments | — | — | — | (400) | — | — | (400) |
| Unrealized gains on available-for-sales securities | — | — | — | 653 | — | — | 653 |
| Net income | — | — | — | — | 370,445 | (2,582) | 367,863 |
| Balance at March 31, 2025 | 138,062 | $230 | $2,106,864 | $4,390 | $(1,428,163) | $904 | $684,225 |
| Stock-based compensation | — | — | 13,043 | — | — | — | 13,043 |
| Exercise of stock options | 36 | — | 223 | — | — | — | 223 |
| Common stock - restricted stock units vesting | 46 | — | — | — | — | — | — |
| Foreign currency translation adjustments | — | — | — | 91 | — | — | 91 |
| Unrealized gains on available-for-sales securities | — | — | — | 876 | — | — | 876 |
| Net loss | — | — | — | — | (175,241) | (3,411) | (178,652) |
| Balance at June 30, 2025 | 138,144 | $230 | $2,120,130 | $5,357 | $(1,603,404) | $(2,507) | $519,806 |
| CommonStock | Amount ($) | AdditionalPaid-InCapital | Accumulated Other Comprehensive Loss | AccumulatedDeficit | Non-controlling Interest | Total | |
|---|---|---|---|---|---|---|---|
| Balance at September 30, 2023 | 107,312 | $200 | $1,300,395 | $(3,222) | $(1,026,030) | $15,819 | $287,162 |
| Stock-based compensation | — | — | 19,694 | — | — | — | 19,694 |
| Exercise of stock options | 34 | — | 267 | — | — | — | 267 |
| Common stock - restricted stock units vesting | 154 | — | — | — | — | — | — |
| Foreign currency translation adjustments | — | — | — | 58 | — | — | 58 |
| Unrealized gains on available-for-sale securities | — | — | — | 1,909 | — | — | 1,909 |
| Net loss | — | — | — | — | (132,864) | (2,512) | (135,376) |
| Balance at December 31, 2023 | 107,500 | $200 | $1,320,356 | $(1,255) | $(1,158,894) | $13,307 | $173,714 |
| Stock-based compensation | — | — | 17,750 | — | — | — | 17,750 |
| Exercise of stock options | 120 | — | 1,512 | — | — | — | 1,512 |
| Common stock - restricted stock units vesting | 723 | 1 | (1) | — | — | — | — |
| Common stock issued, net of offering costs | 15,790 | 16 | 429,249 | — | — | — | 429,265 |
| Foreign currency translation adjustments | — | — | — | (56) | — | — | (56) |
| Unrealized gains on available-for-sale securities | — | — | — | 216 | — | — | 216 |
| Net loss | — | — | — | — | (125,300) | (1,696) | (126,996) |
| Balance at March 31, 2024 | 124,133 | $217 | $1,768,866 | $(1,095) | $(1,284,194) | $11,611 | $495,405 |
| Stock-based compensation | — | — | 17,050 | — | — | — | 17,050 |
| Exercise of stock options | 43 | — | 388 | — | — | — | 388 |
| Common stock - restricted stock units vesting | 51 | — | — | — | — | — | — |
| Foreign currency translation adjustments | — | — | — | (141) | — | — | (141) |
| Unrealized gains on available-for-sale securities | — | — | — | 249 | — | — | 249 |
| Net loss | — | — | — | — | (170,793) | (3,184) | (173,977) |
| Balance at June 30, 2024 | 124,227 | $217 | $1,786,304 | $(987) | $(1,454,987) | $8,427 | $338,974 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.